Lip (2017)

Cohort

(n = 14,020)

NOACs (apixaban, rivaroxaban, dabigatran) vs warfarin

66.5 (61.1 - 70.4)

No significant difference in stroke prevention.

Bleeding events were significantly lower for treatment with apixaban ([HR], 0.35; 95% CI, 0.17 - 0.72) and dabigatran (HR, 0.48; 95% CI, 0.30 - 0.77) vs. warfarin.

Bleeding event was not significantly different for treatment with rivaroxabanvs warfarin (HR, 0.84; 95% CI, 0.49 - 1.44).